HOME >> MEDICINE >> NEWS
Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Philadelphia, PA., May 19, 2003 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that a landmark analysis of studies comparing antidepressant treatments demonstrated that significantly more patients achieved remission (virtual elimination) of their depression symptoms, and resolution of both emotional and physical symptoms, when treated with EFFEXOR/EFFEXOR XR (venlafaxine HCl) than with commonly used selective serotonin reuptake inhibitors (SSRIs) or placebo. The analysis was presented in two poster presentations at the American Psychiatric Association's (APA) annual meeting in San Francisco.

The analysis compared EFFEXOR®/EFFEXOR XR to the SSRIs PAXIL® (paroxetine), PROZAC® (fluoxetine), ZOLOFT® (sertraline), LUVOX® (fluvoxamine), and CELEXA (citalopram) and comprised the entire worldwide dataset of Wyeth-sponsored registration and post-marketing, published and unpublished, SSRI-controlled clinical studies of EFFEXOR/EFFEXOR XR to date.

"Given the urgency to treat a patient to remission, these data reinforce EFFEXOR XR as a first-line therapy for depression," says Dr. Eric Hollander, Professor of Psychiatry and Director of Psychopharmacology at Mount Sinai School of Medicine in New York City. "This is important information for physicians as remission is a critical milestone in preventing symptom recurrence and depression relapse."

In one poster it was determined that EFFEXOR/EFFEXOR XR-treated patients had significantly higher remission rates than those treated with the studied SSRIs using standard evaluations including scoring seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17) and less than 10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Specifically, the HAM-D17 evaluation revealed a 41 percent remission rate for EFFEXOR/EFFEXOR XR patients, significantly greater than that of patients receiving an SSRI (35 percent, p<0.001), or a placebo (25 percent,
'"/>

Contact: Douglas Petkus, Wyeth Pharmaceuticals
484-865-5140
Porter Novelli
19-May-2003


Page: 1 2 3 4

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
3. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
4. Landmark study demonstrates potential for nerve regeneration treatment of stroke
5. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
6. Landmark study uncovers reasons behind recurring back injury
7. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
8. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... International ... Technologies WALI wireless parking lot controller. This advanced LED wireless dimming controller, along ... trespass, and protecting the night sky against light pollution. Leo Smith, the Northeast ...
(Date:9/1/2020)... ... September 01, 2020 , ... Feeding Matters , ... children with Pediatric Feeding Disorder (PFD), is pleased to announce that the U.S. Centers ... diagnostic code (R code) in the next edition of the U.S. International Classification ...
(Date:8/31/2020)... YORK (PRWEB) , ... August 31, 2020 , ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – today announced the 10th Anniversary of Blood Cancer Awareness Month ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... solution for chiropractors, announced today the launch of its integrated, HIPAA compliant, telehealth ... running their virtual practice in under 90 seconds. , According to the ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation ... on the planet are in a state of panic, experiencing deep anxiety, immense stress, and ... now, a solution is timely when most people on the planet are experiencing a great ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... 2020 , ... Austin Oral Surgery – an oral and maxillofacial surgery practice ... DDS, MD, has joined the practice. An accomplished oral and maxillofacial surgeon, Dr. Szalay’s ... scheduled to open this fall. The new office is slated for 1601 E. Pflugerville ...
(Date:8/27/2020)... FORT MYERS, Fla. (PRWEB) , ... August 27, 2020 , ... ... its Board of Directors. Dr. Friedman is an adult and pediatric neuro-oncologist who serves ... Duke University and as an educator at Duke University Medical School. , Internationally recognized, ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... BioPharma Services, Laboratory Testing division, expands its technology footprint with the addition ... Cytometry platforms available. With industry-leading biomarker solutions, complemented with traditional ligand-binding assays ...
Breaking Medicine Technology:
Cached News: